ArticleBMC medical genomics2025
The role of ITGA3 expression in predicting liver metastasis in patients with epithelial ovarian cancer.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Orchestrating Tumor Metastasis: Exosomes as Master Regulators of the Local and Distant Microenvironment.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIntegrin alpha-3 (ITGA3) has been implicated in tumor metastasis in various cancers, but its role in epithelial ovarian cancer (EOC)-associated liver metastasis (LM) remains unclear. This study aimed to investigate its role in LM in primary EOC patients.
methodsIt was a retrospective study with a sample size of n = 235 receiving surgical resection at Puren Hospital Affiliated to Wuhan University of Science and Technology between January 2020 and December 2021, including 98 LM (LM group) and 137 non-LM cases (N-LM group). ITGA3 expression was assessed by immunohistochemistry. ROC curves were used for predictive performance analysis, Kaplan-Meier curves for survival analysis, and Cox regression analysis for identification of risk factors.
resultsMarkedly elevated ITGA3 expression in tumor tissues was found in the LM group (P < 0.001), which demonstrated strong predictive value for LM in EOC patients (area under the curve (AUC) = 0.881, sensitivity = 70.41%, specificity = 87.59%, P < 0.001), and strongly correlated with tumor size and postoperative residual lesions (both P < 0.05). Compared with the L-ITGA3 group, the H-ITGA3 group had a higher incidence of postoperative LM (P < 0.001) and showed a left-shifted curve in Kaplan-Meier analysis (P < 0.001). ITGA3 expression in tumor tissues (HR = 5.977), tumor grade (HR = 1.441), and postoperative residual lesions (HR = 1.697) were identified as independent risk factors for postoperative LM.
conclusionsITGA3 expression in tumor tissue significantly aids in predicting LM in EOC patients and is independently and closely related to adverse clinicopathological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.